CN106511779A - Western medicine composition for treating rheumatism and preparation method thereof - Google Patents

Western medicine composition for treating rheumatism and preparation method thereof Download PDF

Info

Publication number
CN106511779A
CN106511779A CN201611108717.3A CN201611108717A CN106511779A CN 106511779 A CN106511779 A CN 106511779A CN 201611108717 A CN201611108717 A CN 201611108717A CN 106511779 A CN106511779 A CN 106511779A
Authority
CN
China
Prior art keywords
parts
western medicine
stem
noble dendrobium
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611108717.3A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Zhengxian Pharmaceutical Technology Co Ltd
Original Assignee
Zhengzhou Zhengxian Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Zhengxian Pharmaceutical Technology Co Ltd filed Critical Zhengzhou Zhengxian Pharmaceutical Technology Co Ltd
Priority to CN201611108717.3A priority Critical patent/CN106511779A/en
Publication of CN106511779A publication Critical patent/CN106511779A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a western medicine composition for treating rheumatism. The western medicine composition is composed of, by weight, 2-5 parts of auxiliary materials, 3-7 parts of Caulis dendrobii liquid, 1-2 parts of methotrexate, 0.2-1.5 parts of leflunomide, 2-4 parts of oryzanol, 0.2-1 part of vitamin E, 2-4 parts of lysine, 1-4 parts of caffeine, 4-9 parts of cucurbitacine, 0.5-2.5 parts of aspirin, 0.4-2 parts of oxytetracycline, 3-6 parts of glycerinum and 10-18 parts of normal saline. The invention further discloses a preparation method of the medicine composition. The western medicine composition is extensive in source, simple in preparation technique and suitable for large-scale industrialized production. The Caulis dendrobii liquid, the cucurbitacine, the methotrexate and the like play a synergistic effect, the formula is reasonable, using is convenient, the treatment time is short, the rheumatism can be completely treated and is not prone to relapsing, toxic and side effects are avoided, and the using effect is good.

Description

It is a kind of to be used to treat rheumatismal Western medicine combination and preparation method thereof
Technical field
The present invention relates to field of medicine preparation, specifically a kind of to combine for treating rheumatismal Western medicine.
Background technology
Rheumatism is a kind of common disease, and rheumatism is one group of infringement joint, bone, muscle, blood vessel and relevant soft group Knit or connective tissue based on disease, wherein most is autoimmune disease.It is more hidden and slow more than rheumatismal morbidity, disease Journey is longer, and has mostly genetic predisposition.Rheumatism is the autoimmunity that a class invades Various Tissues multisystem and internal organs Property disease, be degree it is different immune inflammation reaction, various tissues and organ damage can be caused into, its normal work(is had a strong impact on Can, or even cause mortality to damage.Additionally, most of rheumatism have joint symptoms.The Western medicine combination for the treatment of rheumatic disease Including nonsteroidal anti-inflammatory agent, cortex hormone of aadrenaline, the slow effect medicine such as antirheumatic and Yun Ke.But existing Western medicine group Conjunction can only alleviate rheumatismal symptom, can not effect a radical cure, and treatment time is long, and cost money is more, and long-term taking has certain west Medicine combines dependence and side effect, and this just brings puzzlement for rheumatisant.
The content of the invention
It is an object of the invention to provide it is a kind of for treating rheumatismal Western medicine combination, to solve in above-mentioned background technology The problem of proposition.
For achieving the above object, the present invention provides following technical scheme：
It is a kind of to combine for treating rheumatismal Western medicine, it is made up of according to weight portion following raw material：Auxiliary material 2-5 parts, the stem of noble dendrobium Liquid 3-7 parts, methotrexate (MTX) 1-2 parts, leflunomide 0.2-1.5 parts, oryzanol 2-4 parts, vitamin E 0.2-1 parts, lysine 2-4 Part, caffeine 1-4 parts, cucurbitacin 4-9 parts, aspirin 0.5-2.5 parts, terramycin 0.4-2 parts, glycerine 3-6 parts and physiology salt Water 10-18 parts.
As further scheme of the invention：Stem of noble dendrobium juice is decocted 2-4 time using the stem of noble dendrobium, each 1-2 hours, is merged and is decocted Rear liquid and remove residue and obtain.
As further scheme of the invention：Auxiliary material using starch, dextrin, PVP, odium stearate, vegetable oil, gelatin, One or several mixture of sodium carboxymethyl starch, atoleine and shellac.
The preparation method for treating rheumatismal Western medicine combination, comprises the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 30-50 Mesh sieve, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, is stirred Machine is mixed at normal temperatures with the rotating speed stirring 15-25 minutes of 120-180rpm, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid while stirring And glycerine, be added completely into and rear stirrer finished under 30-45 degree Celsius with the rotating speed stirring 30-50 minutes of 240-360rpm, obtain To the second mixed solution, then the second mixed solution is concentrated and is dried, obtained dry extract, dry extract is broken into into powder simultaneously And be sufficiently mixed uniformly with auxiliary material, make tablet, pill or capsule.
Compared with prior art, the invention has the beneficial effects as follows：Raw material sources of the present invention extensively, fit by preparation process is simple For large-scale industrial production；In the present invention, the component such as stem of noble dendrobium liquid, cucurbitacin, methotrexate (MTX) plays synergy, and formula is closed Reason, easy to use, treatment time is short, can thoroughly cure rheumatism, is difficult recurrence and no toxic and side effect, using effect It is good.
Specific embodiment
The technical scheme of this patent is described in more detail with reference to specific embodiment.
Embodiment 1
It is a kind of to combine for treating rheumatismal Western medicine, it is made up of according to weight portion following raw material：2 parts of auxiliary material, stem of noble dendrobium liquid 3 Part, 1 part of methotrexate (MTX), 0.2 part of leflunomide, 2 parts of oryzanol, 0.2 part of vitamin E, 2 parts of lysine, 1 part of caffeine, cucurbit 10 parts of 4 parts of element, 0.5 part of aspirin, 0.4 part of terramycin, 3 parts of glycerine and physiological saline.Stem of noble dendrobium juice decocts 3 using the stem of noble dendrobium It is secondary, 1.5 hours every time, merge the liquid after decocting for 3 times and remove residue and obtain.
The preparation method for treating rheumatismal Western medicine combination, comprises the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 30 mesh sieves Son, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, is stirred Mix machine and stirred 18 minutes with the rotating speed of 120rpm at normal temperatures, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid while stirring And glycerine, it is added completely into and finishes rear stirrer under 30 degrees Celsius and stirred 30 minutes with the rotating speed of 270rpm, obtains the second mixing Solution, then the second mixed solution is concentrated and is dried, dry extract is obtained, dry extract is broken into into powder and is filled with auxiliary material Divide and be well mixed, make tablet, pill or capsule.
Embodiment 2
It is a kind of to combine for treating rheumatismal Western medicine, it is made up of according to weight portion following raw material：3 parts of auxiliary material, stem of noble dendrobium liquid 5 Part, 1.4 parts of methotrexate (MTX), 0.8 part of leflunomide, 3 parts of oryzanol, 0.9 part of vitamin E, 2.6 parts of lysine, caffeine 2.5 Part, 6 parts of cucurbitacin, 1.5 parts of aspirin, 1 part of terramycin, 4.5 parts of glycerine and 12 parts of physiological saline.Auxiliary material is using starch, paste The mixture of essence, gelatin, sodium carboxymethyl starch, atoleine and shellac.
The preparation method for treating rheumatismal Western medicine combination, comprises the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 35 mesh sieves Son, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, is stirred Mix machine and stirred 20 minutes with the rotating speed of 150rpm at normal temperatures, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid while stirring And glycerine, it is added completely into and finishes rear stirrer under 36 degrees Celsius and stirred 40 minutes with the rotating speed of 300rpm, obtains the second mixing Solution, then the second mixed solution is concentrated and is dried, dry extract is obtained, dry extract is broken into into powder and is filled with auxiliary material Divide and be well mixed, make tablet, pill or capsule.
Embodiment 3
It is a kind of to combine for treating rheumatismal Western medicine, it is made up of according to weight portion following raw material：4 parts of auxiliary material, stem of noble dendrobium liquid 6 Part, 1.8 parts of methotrexate (MTX), 1.3 parts of leflunomide, 3.5 parts of oryzanol, 0.5 part of vitamin E, 3.6 parts of lysine, caffeine 3 Part, 7 parts of cucurbitacin, 2 parts of aspirin, 1.5 parts of terramycin, 5.2 parts of glycerine and 16 parts of physiological saline.Stem of noble dendrobium juice adopts the stem of noble dendrobium Decoct 4 times, 1 hour every time, merge the liquid after decocting for 4 times and remove residue and obtain.Auxiliary material adopts gelatin.
The preparation method for treating rheumatismal Western medicine combination, comprises the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 30 mesh sieves Son, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, is stirred Mix machine and stirred 22 minutes with the rotating speed of 160rpm at normal temperatures, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid while stirring And glycerine, it is added completely into and finishes rear stirrer under 45 degrees Celsius and stirred 50 minutes with the rotating speed of 300rpm, obtains the second mixing Solution, then the second mixed solution is concentrated and is dried, dry extract is obtained, dry extract is broken into into powder and is filled with gelatin Divide and be well mixed, make tablet, pill or capsule
Embodiment 4
It is a kind of to combine for treating rheumatismal Western medicine, it is made up of according to weight portion following raw material：5 parts of auxiliary material, stem of noble dendrobium liquid 7 Part, 2 parts of methotrexate (MTX), 1.5 parts of leflunomide, 4 parts of oryzanol, vitamin e1 part, 4 parts of lysine, 4 parts of caffeine, cucurbitacin 9 Part, 2.5 parts of aspirin, 2 parts of terramycin, 6 parts of glycerine and 18 parts of physiological saline.Stem of noble dendrobium juice adopts stem of noble dendrobium decoction 3 times, every time 2 hours, merge the liquid after decocting for 3 times and remove residue and obtain.Auxiliary material using starch, dextrin, PVP, odium stearate, The mixture of vegetable oil, gelatin, sodium carboxymethyl starch, atoleine and shellac.
The preparation method for treating rheumatismal Western medicine combination, comprises the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 50 mesh sieves Son, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, is stirred Mix machine and stirred 20 minutes with the rotating speed of 180rpm at normal temperatures, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid while stirring And glycerine, it is added completely into and finishes rear stirrer under 45 degrees Celsius and stirred 40 minutes with the rotating speed of 360rpm, obtains the second mixing Solution, then the second mixed solution is concentrated and is dried, dry extract is obtained, dry extract is broken into into powder and is filled with auxiliary material Divide and be well mixed, make tablet, pill or capsule.
Comparative example
Except stem of noble dendrobium liquid is not contained, remaining component of comparative example 1 and preparation method are same as Example 2.Except not containing calabash Lu Su, remaining component of comparative example 2 and preparation method it is same as Example 3.
Select the rheumatism patient 700 of same condition, stochastic averagina to be divided into 1-7 groups, per group of 100 people, the age of each group and It is essentially identical in sex, patient of the product of embodiment 1-4 to 1-4 groups is taken, the product of comparative example 1 and comparative example 2 is given 5-6 group patients take, and existing product is taken to 7 groups of patient, daily 2 times each 2g and adopt warm water delivery service, two weeks For a course for the treatment of, continue three courses for the treatment of, treatment results are shown in Table 1.
Curative effect determinate standard：Recovery from illness：Rheumatism symptom is wholly absent, and no longer recurs in two years.Take a turn for the better：Rheumatism symptom subtracts It is light more than half.It is invalid：Rheumatism symptom does not mitigate or even increases.
Table 1
As it can be seen from table 1 the cure rate of embodiment 1-4 product and the efficient product for being superior to comparative example 1-2 and existing There is product, therapeutic effect is good.In use, patient does not have any discomfort to the product of embodiment 1-4, and patient is during taking medicine Avoid the irritable food such as pungent, give up alcohol and seafood.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped Containing an independent technical scheme, this narrating mode of specification is only that those skilled in the art should for clarity Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art Understandable other embodiment.

Claims (4)

1. it is a kind of to combine for treating rheumatismal Western medicine, it is characterised in that to be made up of according to weight portion following raw material：Auxiliary material 2- 5 parts, stem of noble dendrobium liquid 3-7 parts, methotrexate (MTX) 1-2 parts, leflunomide 0.2-1.5 parts, oryzanol 2-4 parts, vitamin E 0.2-1 parts, rely Propylhomoserin 2-4 parts, caffeine 1-4 parts, cucurbitacin 4-9 parts, aspirin 0.5-2.5 parts, terramycin 0.4-2 parts, glycerine 3-6 parts and Physiological saline 10-18 parts.
2. it is according to claim 1 to combine for treating rheumatismal Western medicine, it is characterised in that the stem of noble dendrobium juice is adopted The stem of noble dendrobium is decocted 2-4 time, each 1-2 hours, is merged the liquid after decoction and is removed residue and obtain.
3. it is according to claim 1 and 2 to combine for treating rheumatismal Western medicine, it is characterised in that the auxiliary material is adopted Starch, dextrin, PVP, odium stearate, vegetable oil, gelatin, sodium carboxymethyl starch, atoleine and shellac it is a kind of or several The mixture planted.
4. a kind of preparation method for treating the combination of rheumatismal Western medicine as described in claim 1-3 is arbitrary, its feature exist In comprising the following steps that：
Step one, methotrexate (MTX), leflunomide and aspirin are mixed, grind into powder and excessively 30-50 mesh sieves Son, obtains the first mixture, standby；
Step 2, oryzanol, vitamin E, lysine, caffeine, cucurbitacin and terramycin is put in physiological saline, mixer At normal temperatures with the rotating speed stirring 15-25 minutes of 120-180rpm, you can obtain the first mixed solution；
First mixture is added in the first mixed solution and is stirred by step 3, adds stem of noble dendrobium liquid and sweet while stirring Oil, is added completely into and finishes rear stirrer under 30-45 degree Celsius with the rotating speed stirring 30-50 minutes of 240-360rpm, obtains the Two mixed solutions, then the second mixed solution is concentrated and is dried, obtain dry extract, by dry extract be broken into powder and with Auxiliary material is sufficiently mixed uniformly, makes tablet, pill or capsule.
CN201611108717.3A 2016-12-06 2016-12-06 Western medicine composition for treating rheumatism and preparation method thereof Withdrawn CN106511779A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611108717.3A CN106511779A (en) 2016-12-06 2016-12-06 Western medicine composition for treating rheumatism and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611108717.3A CN106511779A (en) 2016-12-06 2016-12-06 Western medicine composition for treating rheumatism and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106511779A true CN106511779A (en) 2017-03-22

Family

ID=58342585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611108717.3A Withdrawn CN106511779A (en) 2016-12-06 2016-12-06 Western medicine composition for treating rheumatism and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106511779A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647801A (en) * 2009-08-11 2010-02-17 华东师范大学 Application of tetracyclic triterpenoids compound in preparing anti-angiogenic drugs
CN102188621A (en) * 2011-05-12 2011-09-21 中国药科大学 Application of total dendrobium crepidatum alkaloids in preparing medicament for treating acute and chronic inflammation, acute and chronic arthritis or rheumatoid arthritis diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647801A (en) * 2009-08-11 2010-02-17 华东师范大学 Application of tetracyclic triterpenoids compound in preparing anti-angiogenic drugs
CN102188621A (en) * 2011-05-12 2011-09-21 中国药科大学 Application of total dendrobium crepidatum alkaloids in preparing medicament for treating acute and chronic inflammation, acute and chronic arthritis or rheumatoid arthritis diseases

Similar Documents

Publication Publication Date Title
CN102342992A (en) Chinese medicinal composition for treating insomnia and preparation method of preparation thereof
CN102784219B (en) Compound pure Chinese medicine composition for treating bovine ephemeral fever and preparation method of same
CN105311060A (en) Traditional Chinese medicine composition for treating oral ulcer and preparation method of traditional Chinese medicine composition
CN106072594A (en) A kind of Auricularia and Fructus Jujubae generation meal fat-reducing nutrient sheet and preparation method thereof
CN103055076B (en) Pure Chinese medicinal composition for treating nosemosis of bees and preparation method of pure Chinese medicinal composition
CN100391494C (en) Compound chinese preparation for treating pain symptom and its preparing process
CN107115493A (en) It is a kind of to treat Chinese medicine composition of fracture and its production and use
CN102727693B (en) Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof
CN102488881B (en) Compound propolis composition for promoting pig growth and fattening as well as its preparation method
CN106511779A (en) Western medicine composition for treating rheumatism and preparation method thereof
TWI693939B (en) Composition for invigorating kidney and strengthening yang, preparation method and application thereof
CN106620283A (en) Medicine for treating rheumatoid arthritis and preparation method thereof
CN102266456B (en) Medicament for treating orthopedic disease and preparation thereof
CN102579568B (en) Pure traditional Chinese medicine composition for treating various hemorrhage diseases and preparation method of same
CN106377677A (en) Medicine for curing rheumatism and preparation method thereof
CN1315509C (en) Medicine for curing pyogenic osteomyelitis and process for preparing the same
CN103690842A (en) Traditional Chinese medicine for treating diarrhea of weaned piglet and preparation method thereof
CN104815311A (en) Traditional Chinese medicine composition for treating pregnancy sickness and preparation method thereof
CN104587128B (en) A kind of medical composition and its use treated first and subtracted
CN106138968A (en) Integration of edible and medicinal herbs compositions of the intestines and stomach reparation and protection gastrointestinal mucosa and preparation method thereof
CN103055090B (en) Pure Chinese medicinal composition for treating fowl cholera and preparation method of pure Chinese medicinal composition
CN100475224C (en) Chinese medicine extract and application thereof
CN104225343A (en) Chinese herbal preparation for treating urinary tract infection and preparation method thereof
CN1151817C (en) Fracture setting granule for treating bone injury and its prepn process
CN105616500A (en) Pharmaceutical composition for treating cestodiasis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170322